Physician profile
Sai Katta
NPI 1568810273
$2,684.36
in general payments reported to CMS, 2019-2025
27 companies · $787 in 2025
The $787 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2022: $402 · 2023: $627 · 2024: $760 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.06 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $418.63 | 2022-2025 | Ozempic |
| Amgen INC. | $362.10 | 2022-2025 | Evenity |
| Lilly USA, LLC | $310.42 | 2022-2024 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $213.77 | 2022-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $177.60 | 2022-2023 | |
| Dexcom, INC. | $155.76 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Medtronic, INC. | $129.61 | 2023-2025 | Minimed 780g, Intellis Adaptivestim, Minimed 630g |
| Kyowa Kirin, INC. | $128.37 | 2024 | Crysvita |
| Corcept Therapeutics | $102.50 | 2022-2023 | Korlym |
| Abbott Laboratories | $102.10 | 2024 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $76.54 | 2023-2025 | Isturisa, Signifor Lar |
| United Therapeutics Corporation | $75.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $53.80 | 2023-2024 | |
| Tandem Diabetes Care, INC. | $51.82 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $46.33 | 2023-2025 | Recorlev |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.54 | 2022-2024 | Jardiance |
| Aimmune Therapeutics, INC. | $28.93 | 2025 | Vowst |
| Radius Health, INC. | $27.76 | 2023 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $25.73 | 2025 | |
| Madrigal Pharmaceuticals | $24.41 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $21.11 | 2025 | Twiist |
| Ibsa Pharma INC. | $20.18 | 2025 | Tirosint, Flector, Licart |
| Astellas Pharma US INC | $19.85 | 2025 | Veozah |
| Ascendis Pharma Endocrinology INC | $18.26 | 2023 | |
| Shire North American Group INC | $18.18 | 2019 | |
| Abbvie INC. | $15.84 | 2025 | |
| La Jolla Pharmaceutical Company | $15.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sai Katta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.